IMUNON, Inc. announced on May 27, 2025, that an abstract highlighting IMNN-001 data based on an immune biomarker analysis from its Phase 2 OVATION 2 Study was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025, scheduled for June 19-21, 2025, in Vienna, Austria.
This presentation will follow the oral presentation of new positive data from the OVATION 2 Study at the 2025 ASCO Annual Meeting and its simultaneous publication in Gynecologic Oncology. The biomarker analysis aims to further elucidate the mechanism of action of IMNN-001.
The company noted strong interest from the global scientific community, including researchers from the European Union and Latin America, in participating in the pivotal Phase 3 trial. This acceptance at ESMO further validates IMNN-001's potential and supports its advancement for regulatory review in international markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.